{"filing":{"accession_number":"0001193125-26-229610","cik":"0001703647","ticker":null,"company_name":"Korro Bio, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"krro-20260519.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526229610/krro-20260519.htm"},"classifications":[{"id":120,"accession_number":"0001193125-26-229610","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Korro Bio announced the addition of KRRO-111 for Alpha-1 Antitrypsin Deficiency to its pipeline, disclosed via press release and updated investor presentation. While this represents a material pipeline expansion for a clinical-stage biotech company that would affect investor assessment of the company's development strategy and future prospects, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or other defined event types). This is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:17:06.944304+00:00","company_name":"Korro Bio, Inc.","ticker":null,"filing_date":"2026-05-19"}]}